Considering intrinsic limits of 18F-FDG PET/CT in brain and neuroendocrine tumors imaging, several radiopharmaceuticals have been developed to investigate these diseases. Among others, a promising tracer is 18F-DOPA, due to its very low rate of physiological distribution in normal brain structures of white and gray matter and the affinity for somatic neuroendocrine tumors. Similar to other amino acid tracers, 18F-DOPA PET/CT is useful in diagnosis of patients with suspected low-grade brain tumor recurrence, because of low signal ratio in normal brain white and gray matter, in particular in comparison to 18F-FDG PET/CT. MRI is the gold standard of diagnosis but 18F-DOPA PET/CT is adjuvant to diagnosis. PET/MRI with 18F-DOPA or other amino acid tracers will play a prevalent role in brain tumor imaging.